A Phase 1, 2-Part Study in Healthy Male and Female Participants; Part 1 - A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose-Escalation Study of Inhaled DMC-IH1; Part 2 - An Open-Label, 3-Arm Study Assessing the Carryover Effects of Inhaled (DMC-IH1) and Intramuscular (EpiPen®) Epinephrine
Overview
- Phase
- Phase 1
- Intervention
- Epinephrine
- Conditions
- Anaphylactic Reaction
- Sponsor
- De Motu Cordis
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Number of participants with changes in the 12-lead electrocardiogram (ECG)
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This is a phase 1, randomised, double blind placebo controlled 2-part study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled DMC-IH1 (epinephrine) and relative bioavailability and carryover effects of Inhaled (DMC-IH1) and Intramuscular(IM) (EpiPen®) Epinephrine in healthy male and female participants.
Detailed Description
DMC-IH1 (Investigational product) inhaler is a proprietary single-use capsule based dry powder inhaler designed for oral pulmonary drug delivery in emergency scenarios. Part 1 will enrol 24 participants into 3 cohorts receiving a single ascending dose. Study will comprise 3 periods: Screening, Treatment Period and Follow-up.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Is willing to sign an ICF on a voluntary basis and to voluntarily participate in the study, after being able to read the ICF and understand the information contained within, prior to any Screening procedure being undertaken.
- •Male or female and ≥18 to ≤45 years of age at time of signing the ICF.
- •Has a BMI of ≥18.00 to ≤30.00 kg/m2, with a minimum body weight of 45.0 kg and a maximum body weight of 120 kg.
- •Is in good health based on the results of medical and surgical history, physical examination, vital sign measurements, and clinical laboratory evaluations, as assessed by the Investigator (or designee).
- •Has a resting heart rate of ≥45 and ≤90 beats per minute; systolic blood pressure of ≥90 but ≤130 mmHg and diastolic blood pressure of ≥50 but ≤90 mmHg at Screening (Visit 1) and prior to randomisation on Day -1 (Visit 2).
- •Has normal lung function assessed using spirometry and defined by forced vital capacity (FVC) ≥ lower limit of normal (LLN), forced expiratory volume in 1 second/FVC ≥LLN, and peak inspiratory flow rate ≥ LLN at Screening (Visit 1).
- •Has no history of anaphylaxis or severe allergy requiring the use of epinephrine.
- •Is a non-smoker/non-vaping; or social smoker who currently only uses ≤5 cigarettes per month and has used nicotine on ≤5 occasions within 30 days prior to Screening, a negative cotinine test at Visit 2/Day -1, and ability and willingness to refrain from smoking 7 days prior to the first epinephrine dose through the EOS \[Part 1: Visit 3\].
- •Has adequate venous access.
- •Is able to demonstrate correct use of the device using a practice device and follow directions for use.
Exclusion Criteria
- •Participant who is pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time from screening to the end of study visit (Part 1: through Visit 3/EOS).
- •Participant has a history of significant hypersensitivity or intolerance to lactose and/or epinephrine.
- •Participant has a history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular (including severe pulmonary haemorrhage), gastrointestinal, neurological (including history of migraine requiring specific treatment), respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee) except for fully resolved childhood asthma.
- •Participant has a positive urine drug screen at Screening and at Baseline (Visit 2/Day -1).
- •Participant has a positive urine cotinine test at Baseline (Visit 2/Day -1).
- •Participant took part in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to Baseline (Visit 2/Day -1).
- •Participant used or intends to use any prescription or non-prescription medications/products within 14 days prior to randomization (Day -1) through EOS (Part 1: Visit 3/EOS), with the exception of paracetamol/acetaminophen at the discretion of the Investigator, and contraceptives.
- •Participant has a history of alcoholism or substance or drug abuse-related disorders deemed significant by the Investigator (or designee) (ie, \>14 drinks/week for women or \>21 drinks/week for men \[1 drink=150 mL of wine or 360 mL of beer or 45 mL of hard liquor\]) within the last 3 months prior to Screening (Visit 1) and randomization (Day -1/Visit 2).
- •Participant has a positive alcohol breath test at Screening and prior to randomization (Day -1/Visit 2).
- •Female participant has a positive serum pregnancy test at Screening and a positive urine pregnancy test prior to randomization (Day -1/Visit 2).
Arms & Interventions
Epinephrine
Dosage Level: Part 1 of the study: Participants across cohort 1 to 3 will receive a single dose of either 1mg or 1.3mg or 1.5mg respectively of epinephrine or placebo via DMC-IHI device. Dosage form: Single-use capsule based dry powder inhaler Route of administration: Inhalation
Intervention: Epinephrine
Epinephrine
Dosage Level: Part 1 of the study: Participants across cohort 1 to 3 will receive a single dose of either 1mg or 1.3mg or 1.5mg respectively of epinephrine or placebo via DMC-IHI device. Dosage form: Single-use capsule based dry powder inhaler Route of administration: Inhalation
Intervention: Placebo
Placebo
Drug: Placebo Participants will receive matching placebo across the study.
Intervention: Epinephrine
Placebo
Drug: Placebo Participants will receive matching placebo across the study.
Intervention: Placebo
Outcomes
Primary Outcomes
Number of participants with changes in the 12-lead electrocardiogram (ECG)
Time Frame: Upto 7 days for Part 1
Number of participants with adverse events (AEs)
Time Frame: Upto 7 days for Part 1
Number of participants with clinical laboratory abnormalities
Time Frame: Upto 7 days for Part 1
PK Parameters: Assess timepoints of carryover effect of repeated dose of inhaled epinephrine
Time Frame: Part 1: Pre-dose and multiple timepoints post dose on Day 1.
Secondary Outcomes
- PK Parameters: Area under Curve (AUC)(Part 1: Pre-dose multiple timepoints post-dose on Day 1.)
- PD parameters: Time to maximum effect (TEmax)(Part 1: 240 minutes postdose.)
- PK Parameters: Maximum concentration (Cmax)(Part 1: Pre-dose multiple timepoints post-dose on Day 1.)
- PD parameters: Maximum effect on heart rate and blood pressure (Emax)(Part 1: 240 minutes postdose.)
- PK Parameters: Time for maximum concentration (Tmax)(Part 1: Pre-dose multiple timepoints post-dose on Day 1.)